Peter de Waele
Director Ejecutivo en Advanced Therapies Consulting Limited .
Perfil
Peter de Waele is the founder of Xcellentis NV, which was founded in 2001, where he held the title of Chief Operating Officer in 2006.
He is currently the Managing Director at Advanced Therapies Consulting Limited.
Dr. de Waele's former positions include Chief Therapeutics Officer at Fujirebio Europe NV, Assistant Professor at Ghent University in 1986, and Vice President-Research & Development at Celyad Oncology SA from 2010 to 2017.
Dr. de Waele received his graduate and doctorate degrees from Ghent University.
Cargos activos de Peter de Waele
| Empresas | Cargo | Inicio |
|---|---|---|
| Advanced Therapies Consulting Limited | Director Ejecutivo | - |
Antiguos cargos conocidos de Peter de Waele.
| Empresas | Cargo | Fin |
|---|---|---|
| CELYAD ONCOLOGY SA | Director Técnico/Científico/I+D | - |
| Xcellentis NV | Fundador | 01/01/2006 |
| Ghent University | Corporate Officer/Principal | 01/01/1986 |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Corporate Officer/Principal | - |
Formación de Peter de Waele.
| Ghent University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| CELYAD ONCOLOGY SA | Health Technology |
| Empresas privadas | 3 |
|---|---|
| Xcellentis NV | Health Technology |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Health Technology |
| Advanced Therapies Consulting Limited |
- Bolsa de valores
- Insiders
- Peter de Waele
